FABP4: a novel candidate gene for polycystic ovary syndrome

Wang, Jing; Tang, Jingwen; Wang, Binbin; Song, Jie; Liu, Jingjing; Wei, Zhaolian; Zhang, Feng; Ma, Xu; Cao, Yunxia

doi:10.1007/s12020-009-9228-5

Cited by 22 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…144 In an independent study, the same variant in the FABP4 promoter resulted in reduced FABP4 expression and was associated with decreased total cholesterol levels and reduced risk of myocardial infarction in patients with advanced atherosclerosis. 145 Moreover, in other small studies an association between FABP4 polymorphisms, plasma levels of FABP4 and metabolic outcome in polycystic ovary syndrome, 146 and obstructive sleep apnoea 147 have been found. Consequently, overwhelming biochemical and genetic evidence demonstrates an important correlation between circulating levels of FABP4 and metabolic disease, which raises the possibility that targeting this form of the molecule might be a useful therapeutic intervention.…”

Section: Circulating Fabp4 and Metabolic Pathologymentioning

confidence: 89%

Metabolic functions of FABPs—mechanisms and therapeutic implications

Hotamışlıgil¹,

2015

View full text Add to dashboard Cite

Intracellular and extracellular interactions with proteins enables the functional and mechanistic diversity of lipids. Fatty acid-binding proteins (FABPs) were originally described as intracellular proteins that can affect lipid fluxes, metabolism and signalling within cells. As the functions of this protein family have been further elucidated, it has become evident that they are critical mediators of metabolism and inflammatory processes, both locally and systemically, and therefore are potential therapeutic targets for immunometabolic diseases. In particular, genetic deficiency and small molecule-mediated inhibition of FABP4 (also known as aP2) and FABP5 can potently improve glucose homeostasis and reduce atherosclerosis in mouse models. Further research has shown that in addition to their intracellular roles, some FABPs are found outside the cells, and FABP4 undergoes regulated, vesicular secretion. The circulating form of FABP4 has crucial hormonal functions in systemic metabolism. In this Review we discuss the roles and regulation of both intracellular and extracellular FABP actions, highlighting new insights that might direct drug discovery efforts and opportunities for management of chronic metabolic diseases.

show abstract

Section: Circulating Fabp4 and Metabolic Pathologymentioning

confidence: 89%

Metabolic functions of FABPs—mechanisms and therapeutic implications

Hotamışlıgil¹,

2015

View full text Add to dashboard Cite

show abstract

“…Besides binding to long-chain fatty acids, FABP4 is also capable of binding to a variety of hydrophobic compounds, including cycloxygenases and oxidative products of fatty acids. It functions in both glucose and lipid metabolism [29, 30], and is involved in signal transduction [31], as well as in cell proliferation and apoptotic processes [32]. Its involvement in tumorigenesis has been investigated in bladder cancer [12], breast cancer [33, 34], ovarian cancer [35, 36], and oral squamous cell cancer [37].…”

Section: Discussionmentioning

confidence: 99%

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)

et al. 2016

View full text Add to dashboard Cite

Fatty acid binding proteins (FABPs) are intracellular lipid-binding proteins that are involved in a variety of biological cellular processes, including tumorigenesis. In this study, we explored the expression pattern of FABP3 and FABP4 in non-small cell lung cancer (NSCLC) as well as their roles in prognosis. We determined mRNA expression of FABP3 and FABP4 in matched pairs of cancerous and non-cancerous fresh frozen tissues from 30 NSCLC patients. Tissue microarray immunohistochemical analysis (TMA-IHC) was applied to determine the protein expression of FABP3 and FABP4 in 281 cancerous and 121 matched adjacent non-cancerous tissue samples. Our results showed that both mRNA and protein expression of FABP3 and FABP4 were significantly higher in cancerous tissues when compared to non-cancerous tissues. Furthermore, high expression of FABP3 or FABP4 in NSCLC was significantly associated with advanced tumor node metastasis (TNM) stage and had a negative impact on the overall survival of NSCLC patients. Concurrent high expression of FABP3 and FABP4 was significantly related to TNM stage. In conclusion, our research demonstrated that high FABP3 or FABP4 expression had strong prognostic value for overall survival in NSCLC. Detection of FABP3 and FABP4 cooperatively was helpful to predict the prognosis of NSCLC.

show abstract

“…However, data from both rodents and humans suggest that it is also secreted by adipose tissue into the bloodstream [13]. Recent studies have confirmed its roles in various conditions associated with insulin resistance, including MS, diabetes mellitus, nonalcoholic fatty liver disease, Cushing's syndrome, and polycystic ovary disease [14-18]. The aim of our study was to evaluate the correlations between A-FABP, systemic inflammation, and insulin resistance associated with critical illness, and further to investigate its role in outcome prediction.…”

Section: Introductionmentioning

confidence: 99%

Serum adipocyte fatty acid-binding protein levels in patients with critical illness are associated with insulin resistance and predict mortality

Huang

Hsieh

et al. 2013

Crit Care

View full text Add to dashboard Cite

IntroductionHyperglycemia and insulin resistance are commonplace in critical illness, especially in patients with sepsis. Recently, several hormones secreted by adipose tissue have been determined to be involved in overall insulin sensitivity in metabolic syndrome-related conditions, including adipocyte fatty-acid binding protein (A-FABP). However, little is known about their roles in critical illness. On the other hand, there is evidence that several adipose tissue gene expressions change in critically ill patients.MethodsA total of 120 patients (72 with sepsis, 48 without sepsis) were studied prospectively on admission to a medical ICU and compared with 45 healthy volunteers as controls. Various laboratory parameters and metabolic and inflammatory profiles were assessed within 48 hours after admission. Clinical data were collected from medical records.ResultsCompared with healthy controls, serum A-FABP concentrations were higher in all critically ill patients, and there was a trend of higher A-FABP in patients with sepsis. In multivariate correlation analysis in all critically ill patients, the serum A-FABP concentrations were independently related to serum creatinine, fasting plasma glucose, total cholesterol, TNF-alpha, albumin, and the Acute Physiology and Chronic Health Evaluation II scores. In survival analysis, higher A-FABP levels (> 40 ng/ml) were associated with an unfavorable overall survival outcome, especially in sepsis patients.ConclusionsCritically ill patients have higher serum A-FABP concentrations. Moreover, A-FABP may potentially serve as a prognostic biomarker in critically ill patients with sepsis.

show abstract

FABP4: a novel candidate gene for polycystic ovary syndrome

Abstract: The present study is the first to establish an association between FABP4 gene polymorphisms and the development of PCOS.

Cited by 22 publications

References 31 publications

Metabolic functions of FABPs—mechanisms and therapeutic implications

Metabolic functions of FABPs—mechanisms and therapeutic implications

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)

Serum adipocyte fatty acid-binding protein levels in patients with critical illness are associated with insulin resistance and predict mortality

Contact Info

Product

Resources

About